# Persistent Lactate Elevation in a Patient with Asthma Exacerbation and a Congenital Portosystemic Shunt: A Case Report and Literature Review

**Authors:** Wing Fai Li, Bailey Fink, Rehnuma Khan, Xinmiao Luo, Muhammad Fahimuddin

PMC · DOI: 10.3390/reports8010008 · 2025-01-17

## TL;DR

An elderly man with asthma and a liver shunt had high lactate levels due to a rare combination of factors, highlighting the need for careful evaluation of lactic acidosis.

## Contribution

This case report highlights a rare association between congenital portosystemic shunts and beta-agonist-induced type B lactic acidosis.

## Key findings

- A 95-year-old patient with asthma exacerbation and a congenital portosystemic shunt had persistent hyperlactatemia.
- Beta-adrenergic agonists may contribute to type B lactic acidosis in patients with impaired lactate clearance.
- Structural liver abnormalities may play a role in reduced lactate metabolism.

## Abstract

Background and Clinical Significance: When lactate production surpasses the body’s clearance capacity, hyperlactatemia (lactate ≥ 2 mmol/L) or lactic acidosis (lactate ≥ 4 mmol/L) can develop. Lactic acidosis is classified into type A, which arises from regional or global tissue hypoperfusion, and type B, resulting from metabolic disturbances without tissue hypoxia. Type A lactic acidosis, often associated with conditions like sepsis or shock, is a critical marker of life-threatening conditions, whereas type B lactic acidosis is less frequently recognized in clinical practice. Case Presentation: A 95-year-old man presents with an asthma exacerbation and is treated with an albuterol inhaler. However, he is found to have persistently high lactate levels. Further investigation reveals a congenital intrahepatic portosystemic shunt on imaging. This, in conjunction with the ongoing use of beta-adrenergic receptor agonists, contributes to the development of type B lactic acidosis. Conclusions: The impact of lactic acidosis depends on its severity and clinical context. While beta agonists are a recognized cause of type B lactic acidosis, a potential role for structural liver abnormalities in reduced lactate clearance must be examined further.

## Linked entities

- **Chemicals:** albuterol (PubChem CID 2083)
- **Diseases:** asthma (MONDO:0004979), lactic acidosis (MONDO:0006040), congenital portosystemic shunt (MONDO:0018811)

## Full-text entities

- **Diseases:** sepsis (MESH:D018805), Asthma (MESH:D001249), liver abnormalities (MESH:D008107), shock (MESH:D012769), Lactic acidosis (MESH:D000140), hyperlactatemia (MESH:D065906), hypoxia (MESH:D000860), metabolic disturbances (MESH:D024821)
- **Chemicals:** albuterol (MESH:D000420), Lactate (MESH:D019344), beta agonists (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12199981/full.md

---
Source: https://tomesphere.com/paper/PMC12199981